Literature DB >> 12731671

Acute myelogenous leukemia M5b developed during clinical remission of Castleman disease.

Akira Tomonari1, Naoki Shirafuji, Arinobu Tojo, Tohru Iseki, Jun Ooi, Itaru Komiya, Kenzaburo Tani, Shigetaka Asano.   

Abstract

Castleman disease (CD) is a rare heterogeneous lymphoproliferative disease characterized by clinical symptoms due to an excess of interleukin-6 (IL-6) or IL-6-like activity. We describe the first case of CD associated with acute myelogenous leukemia (AML). A 55-year-old man presented with skin rash on his face and multiple cervical lymphadenopathy. The results of examination of his lymph node biopsy specimen led to a diagnosis of CD. The symptoms resolved after the administration of prednisolone. Three years after the onset of CD, the patient's white blood cell count had increased to 63.4 x 10(9)/L. His bone marrow aspirate showed that approximately 80% of cells were leukemic, including well-differentiated monocytic cells A diagnosis of AML M5b was made. The patient died of invasive pulmonary aspergillosis after chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12731671     DOI: 10.1007/BF02983785

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.319


  11 in total

1.  [A case report of Castleman's disease in a patient with endometrioid adenocarcinoma of the ovary].

Authors:  D Bertero; M Buzio; B Albertino; M Giaccone; E Ricci
Journal:  Minerva Chir       Date:  1991-09-30       Impact factor: 1.000

Review 2.  Follicular dendritic cell sarcoma. Clinicopathologic analysis of 17 cases suggesting a malignant potential higher than currently recognized.

Authors:  J K Chan; C D Fletcher; S J Nayler; K Cooper
Journal:  Cancer       Date:  1997-01-15       Impact factor: 6.860

3.  Autoimmune cytopenias in Castleman's disease.

Authors:  P A Carrington; H Anderson; M Harris; S E Walsh; J B Houghton; G R Morgenstern
Journal:  Am J Clin Pathol       Date:  1990-07       Impact factor: 2.493

4.  Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease.

Authors:  K Yoshizaki; T Matsuda; N Nishimoto; T Kuritani; L Taeho; K Aozasa; T Nakahata; H Kawai; H Tagoh; T Komori
Journal:  Blood       Date:  1989-09       Impact factor: 22.113

Review 5.  [Association of Castleman's disease and Hodgkin's disease. Eight cases and review of the literature].

Authors:  V Molinié; G Périé; I Mélo; C Melo; J Audouin; J Diebold
Journal:  Ann Pathol       Date:  1994       Impact factor: 0.407

6.  A systemic lymphoproliferative disorder with morphologic features of Castleman's disease: clinical findings and clinicopathologic correlations in 15 patients.

Authors:  G Frizzera; B A Peterson; E D Bayrd; A Goldman
Journal:  J Clin Oncol       Date:  1985-09       Impact factor: 44.544

7.  Primary Sjögren's syndrome associated with hyaline-vascular type of Castleman's disease and autoimmune idiopathic thrombocytopenia.

Authors:  K Higashi; Y Matsuki; T Hidaka; S Aida; K Suzuki; H Nakamura
Journal:  Scand J Rheumatol       Date:  1997       Impact factor: 3.641

8.  Development of vascular neoplasia in Castleman's disease. Report of seven cases.

Authors:  W Gerald; M Kostianovsky; J Rosai
Journal:  Am J Surg Pathol       Date:  1990-07       Impact factor: 6.394

9.  [A case of retroperitoneal Castleman's disease associated with bladder tumor and a review of 59 cases in Japan].

Authors:  H Morishita; T Kobayashi; K Kunimi; T Amano; K Koshida; T Uchibayashi; H Hisazumi; K Naito
Journal:  Hinyokika Kiyo       Date:  1992-09

10.  Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease.

Authors:  J Soulier; L Grollet; E Oksenhendler; P Cacoub; D Cazals-Hatem; P Babinet; M F d'Agay; J P Clauvel; M Raphael; L Degos
Journal:  Blood       Date:  1995-08-15       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.